Amarin Corp Plc (AMRN)

[sts66]

Not for R-IT, it's only for MARINE indication:

Following regulatory approval, EDDING is now focusing on National Reimbursement Drug Listing (NRDL) and preparing for commercial launch in China, expected by year-end, as well as on advancing regulatory submission and review for an additional indication in cardiovascular risk reduction (CVRR).

Given how long it took to get approval for high TG indication it'll probably be at least another year before China approves R-IT indication, then price negotiations need to be done - might be at least two years before Eddingpharm is selling V for R-IT. I don't know about China's laws about prescribing drugs off-label, but most state-run drug benefit plans don't pay for off-label, so I doubt we'll see V being sold in China this year to R-IT patients.